Letter to Governor Kemp on Vaccines for Essential Workers

Earlier this week, Georgia Bio sent a letter to Governor Kemp requesting that the state consider certain biotechnology industry personnel who reside and/or work in Georgia to be considered as essential workers slated to receive a COVID-19 vaccine during the early phases of immunization. Specifically, we requested that workers involved in research, development, manufacturing and distribution of biopharmaceuticals and agricultural biotechnology products be included in Phase 1B of the CDC’s Advisory Committee on Immunization Practices (ACIP) framework in hopes of mitigating any disruption to our state and nation’s medicine and food supply during the pandemic.

Click HERE to view the entire letter.

The post Letter to Governor Kemp on Vaccines for Essential Workers appeared first on Georgia Bio.

< Older Post

Newer Post >

September GBG Report Now Available – Federal Funding Insights for Georgia Life Sciences Members

September 11, 2025

Members are invited to join G2G’s Monthly GBG Reporting Service Webinar on September 18, 2025 . The first portion ( 12:00–12:30 PM ET ) is free and open to all, offering a high-level overview of current federal funding trends. The second half ( 12:30–1:00 PM ET ) is a premium consultation available only to Georgia Life Sciences members, offering direct access to G2G’s expert team—who have helped secure over $550 million in non-dilutive government funding since 2007. Register here: https://www.g2gconsulting.com/event/non-dilutive-funding-g2gs-monthly-gbg-reporting-service-webinar-14-3/2025-09-18/ Key opportunities this month include DARPA’s Expedited Research Innovation System for CBRN threat defense technologies, BARDA’s I-CREATE diagnostic funding and VANGUARD biomanufacturing tools development (each offering up to $200,000), NIAID tuberculosis and influenza research units (up to $1.5–$2.5 million annually), DoD’s $4 million Advanced Medical Monitor development through MTEC, and multiple SBIR opportunities for sensors and field-deployable diagnostics (up to $209,575 for Phase I awards). The September GBG report highlights 13 immunology and infectious disease opportunities, 10 cognitive and brain health programs, and several biotechnology and biomanufacturing initiatives across federal agencies including the Army, ARPA-H, BARDA, and NSF. Georgia Life Sciences members can access the complete 29-page report with detailed deadlines and eligibility requirements [insert link or portal instructions here]. GLS members can access the full 29-page report with deadlines and submission details by logging into your member portal.